Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | POLRMT | O00411 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719238 | 0.91 | POLRMT (0.48) | TMPRSS2POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL26326132 | 0.91 | TMPRSS2 (0.49) | TMPRSS2POLRMTP2RY1P2RY2SRC | |
| SCHEMBL26326152 | 0.90 | TMPRSS2 (0.44) | TMPRSS2POLRMTP2RY1ENTPD1 | |
| SCHEMBL17719237 | 0.90 | TMPRSS2 (0.50) | TMPRSS2POLRMTP2RY1P2RY2SRC | |
| SCHEMBL18298281 | 0.89 | TMPRSS2 (0.51) | TMPRSS2POLRMTP2RY1P2RY2SRC | |
| Rdv-Tp SCHEMBL24492746 | 0.89 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1P2RX1P2RX3 | |
| Rdv-Tp SCHEMBL10120881 | 0.89 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1P2RX1P2RX3 | |
| Rdv-Tp SCHEMBL24492745 | 0.89 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1P2RX1P2RX3 | |
| Rdv-Tp SCHEMBL23278555 | 0.89 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1P2RX1P2RX3 | |
| Rdv-Tp SCHEMBL26003192 | 0.89 | POLRMT (0.51) | TMPRSS2POLRMTP2RY1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885POLRMT 138/4885P2RY1 991/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885POLRMT 138/4885P2RY1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.